Ken Griffin Medpace Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$320.58 - $457.29 $1.96 Million - $2.79 Million	6,100 Added 64.21%	15,600 $5.2 Million
Q2 2024 Aug 14, 2024	SELL	$372.0 - $424.34 $10.7 Million - $12.2 Million	-28,800 Reduced 75.2%	9,500 $3.91 Million
Q1 2024 May 15, 2024	BUY	$284.87 - $413.31 $5.5 Million - $7.98 Million	19,300 Added 101.58%	38,300 $15.5 Million
Q4 2023 Feb 14, 2024	SELL	$227.52 - $312.68 $1.16 Million - $1.59 Million	-5,100 Reduced 21.16%	19,000 $5.82 Million
Q3 2023 Nov 14, 2023	SELL	$233.98 - $281.67 $701,940 - $845,010	-3,000 Reduced 11.07%	24,100 $5.84 Million
Q2 2023 Aug 14, 2023	BUY	$187.26 - $240.17 $2.28 Million - $2.93 Million	12,200 Added 81.88%	27,100 $6.51 Million
Q1 2023 May 15, 2023	BUY	$174.31 - $239.52 $644,947 - $886,224	3,700 Added 33.04%	14,900 $2.8 Million
Q4 2022 Feb 14, 2023	SELL	$153.06 - $226.57 $5.46 Million - $8.09 Million	-35,700 Reduced 76.12%	11,200 $2.38 Million
Q3 2022 Nov 14, 2022	BUY	$145.13 - $182.49 $2.03 Million - $2.55 Million	14,000 Added 42.55%	46,900 $7.37 Million

617

25.1M

42.8K

207K

Ticker MEDP
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 31,099,900
Market Cap $9.66B
Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, bi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.